0
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Editorial | 
Deepak L. Bhatt, MD, MPH
JAMA. 2011;305(18):1908-1909. doi:10.1001/jama.2011.600.

Original Contribution |  FREE
Samer S. Najjar, MD; Sunil V. Rao, MD; Chiara Melloni, MD, MHS; et al.
JAMA. 2011;305(18):1863-1872. doi:10.1001/jama.2011.592.
Includes: Supplemental Content

Sign In

Register for a FREE personal account

and access these and other features:

Register Now

Want to Subscribe?

Learn More about subscription options.

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

From The JAMA Network
JAMA Internal Medicine
Original Investigation  | 
Nononcologic Use of Human Recombinant Erythropoietin Therapy in Hospitalized Patients
Michael A. Fischer, MD, MS; Charles A. Morris, MD, MPH; Wolfgang C. Winkelmayer, MD, ScD; et al.
JAMA Internal Medicine
Editor's Correspondence  | 
Erythropoietin Resistance During Androgen Deficiency—Reply
Jerry L. Spivak, MD
JAMA Internal Medicine
Review Article  | 
Epoetin Alfa:  Clinical Evolution of a Pleiotropic Cytokine
David H. Henry, MD; Peter Bowers, MD; Michael T. Romano, PhD; et al.
JAMA Pediatrics
Article  | 
Comparison of 2 Iron Doses in Infants Receiving Recombinant Human Erythropoietin Therapy
Shahid Nazir, MD; Ricardo L. Peverini, MD; Douglas D. Deming, MD; et al.